MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
68.56
+0.16
+0.23%
After Hours: 68.56 0 0.00% 16:20 03/10 EDT
OPEN
68.41
PREV CLOSE
68.40
HIGH
71.00
LOW
67.98
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
87.50
52 WEEK LOW
35.95
MARKET CAP
5.68B
P/E (TTM)
8.81
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PTCT last week (0302-0306)?
Weekly Report · 1d ago
Controversial Prasad leaving FDA, NYT reports
TipRanks · 2d ago
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
The Motley Fool · 03/03 15:11
BUZZ-Street View: Tough path ahead for uniQure after FDA setback on Huntington's therapy
Reuters · 03/03 14:20
Oversold Conditions For PTC Therapeutics (PTCT)
NASDAQ · 03/02 17:03
Cantor downgrades uniQure to Neutral on FDA setback
TipRanks · 03/02 15:45
Weekly Report: what happened at PTCT last week (0223-0227)?
Weekly Report · 03/02 10:34
Assessing PTC Therapeutics (PTCT) Valuation After Contrasting Quarterly Loss And Full Year Profit Turnaround
Simply Wall St · 03/01 23:25
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.